InSphero's Scientific Ambassador Sue Grepper, Ph.D., highlights how to recapitulate clinically observed increases of Aspartate Transaminase (AST) levels in preclinical in vitro safety studies. If you have experienced a clinical […]
An ongoing challenge in NASH Drug Discovery is selecting “fit for purpose” models for preclinical drug screening. InSphero liver expert Sue Grepper and Head of Liver Solutions Eva Thoma recently […]
Model systems, whether laboratory animals or human cell-based systems, have long been central to the discovery and development of new and better drugs for the treatment of human disease. But […]
InSphero Senior Application Scientist Sue Grepper explains why critical limitations of dietary and genetically modified rodent models for NASH may be slowing down drug discovery efforts in this blog. She […]
In honor of the inaugural International NASH Day, Insphero explains why we need better preclinical models for non-alcoholic steatohepatitis (NASH) disease drug discovery. Non-alcoholic fatty liver disease (NAFLD) is one of […]